IP Verse

Multiple Antigen Binding Molecular Fusion, Pharmaceutical Composition, Method For Identifying Linear Epitope, And Method For Preparing Multiple Antigen Binding Molecular Fusion - EP3296395

The patent EP3296395 was granted to Chugai Seiyaku Kabushiki Kaisha on Jun 19, 2024. The application was originally filed on May 13, 2016 under application number EP16792788A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3296395

CHUGAI SEIYAKU KABUSHIKI KAISHA
Application Number
EP16792788A
Filing Date
May 13, 2016
Status
Patent Maintained As Amended
May 17, 2024
Grant Date
Jun 19, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

JAMES POOLEMar 25, 2022CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (20) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTJP2013528569
INTERNATIONAL-SEARCH-REPORTJP2014519322
INTERNATIONAL-SEARCH-REPORTJP2015509951
INTERNATIONAL-SEARCH-REPORTJP2015509952
INTERNATIONAL-SEARCH-REPORTWO2012073985
INTERNATIONAL-SEARCH-REPORTWO2014144722
INTERNATIONAL-SEARCH-REPORTWO2015046554
INTERNATIONAL-SEARCH-REPORTWO2016014974
INTERNATIONAL-SEARCH-REPORTWO2016046778
OPPOSITIONEP3070168
OPPOSITIONJP2015098208
OPPOSITIONWO2011121110
OPPOSITIONWO2013128027
OPPOSITIONWO2013128194
OPPOSITIONWO2014144722
OPPOSITIONWO2015013671
OPPOSITIONWO2016014974
OPPOSITIONWO2016046778
OPPOSITIONWO2016179003
SEARCHWO2013128194

Non-Patent Literature (NPL) Citations (13) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- GUTHRIDGE JM et al., "Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/ CD 21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.", J. Immunol., (20011115), vol. 167, no. 10, pages 5758 - 5766, XP002318006 [Y] 13 * , Abstract *-
INTERNATIONAL-SEARCH-REPORT- KJER-NIELSEN L et al., "Crystal structure of the human T cell receptor CD 3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3", Proc. Natl. Acad. Sci. USA, (20040000), vol. 101, no. 20, pages 7675 - 7680, XP055329073 [Y] 13 * , Fig. 4 *
INTERNATIONAL-SEARCH-REPORT- FERNANDES RA et al., "T cell receptors are structures capable of initiating signaling in the absence of large conformational rearrangements.", J. Biol. Chem., (20120000), vol. 287, no. 16, pages 13324 - 13335, XP055329084 [Y] 13 * , FIGURE3 *
INTERNATIONAL-SEARCH-REPORT- PONOMARENKO J et al., "ElliPro: a new structure-based tool for the prediction of antibody epitopes.", BMC Bioinformatics, (20080000), vol. 9, no. 514, pages 1 - 8, XP021041865 [Y] 13 * , Abstract *
OPPOSITION- Cytomx Therapeutics Inc., "Probody ™ therapeutics enhance therapeutic window in multiple antibody modalities", Antibody engineering & therapeutics 2015, (20150101), pages 1 - 31, XP055909711-
OPPOSITION- Sherry L Laporte, Daniel R Hostetter; Laurie Wong; Jennifer Razo; Linnea Diep; Clayton W White; Jennifer H Richardson; Michael Kavanaugh W; And Bryan A Irving, "CD3-EGFR Probody™ T Cell-engaging Bispecific Therapeutic Induces Tumor Regressions and Substantially Increases Safety Window in Preclinical Studies", CytomX Therapeutics, Inc., (20150101), page 1, XP055909695-
OPPOSITION- Sherry L. Laporte, Daniel R. Hostetter, Laurie Wong, Jennifer Razo, Linnea Diep, Clayton W. White, Jennifer H. Richardson, W. Michael Kavanaugh, And Bryan A. Irving, "Abstract A203: CD3-EGFR bispecific Probody™ therapeutics induced tumor regressions and increased therapeutic window in preclinical studies", Molecular Cancer Therapeutics, (20151201), pages 1 - 4, Molecular Cancer Therapeutics, URL: https://mct.aacrjournals.org/content/14/12_Supplement_2/A203, (20220210), XP055890402-
OPPOSITION- TURK B E, ET AL, "Determination of protease cleavage site motifs using mixture-based oriented peptide libraries.", Nature Biotechnology, Nature Publishing Group US, New York, New York, (20010701), vol. 19, no. 7, doi:10.1038/90273, ISSN 1087-0156, pages 661 - 667, XP002254824
OPPOSITION- Matthias Pauthner, Jenny Yeung, Chris Ullman, Joost Bakker, Thierry Wurch, Janice M. Reichert, Fridtjof Lund-Johansen, Andrew R.M. Bradbury, Paul J. Carter, Joost P.M. Melis, "Antibody engineering & therapeutics, the annual meeting of the antibody society December 7–10, 2015, San Diego, CA, USA", mAbs, Landes Bioscience, US, US , (20160402), vol. 8, no. 3, doi:10.1080/19420862.2016.1153211, ISSN 1942-0862, pages 617 - 652, XP055291306
OPPOSITION- MAYNARD J, GEORGIOU G, "ANTIBODY ENGINEERING", ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, ANNUAL REVIEW INCO., PALO ALTO, CA, US, US , (20000101), vol. 02, doi:10.1146/annurev.bioeng.2.1.339, pages 339 - 376, XP009039750
OPPOSITION- Krishna R Polu, Henry B Lowman, "Probody therapeutics for targeting antibodies to diseased tissue", EXPERT OPINION ON BIOLOGICAL THERAPY, Informa Healthcare, (20140801), vol. 14, no. 8, doi:10.1517/14712598.2014.920814, ISSN 1471-2598, pages 1049 - 1053, XP055228738
SEARCH- IGAWA TOMOYUKI, "Next Generation Antibody Therapeutics Using Bispecific Antibody Technology", YAKUGAKU ZASSHI, (201707), vol. 137, no. 7, ISSN 0031-6903, pages 831 - 836, XP002785811 [T] * abstract *-
SEARCH- CHATENOUD L, "CD3-SPECIFIC ANTIBODY-INDUCED ACTIVE TOLERANCE: FROM BENCH TO BEDSIDE", NATURE REVIEWS IMMUNOLOGY, NATURE PUB. GROUP, GB, (20030201), vol. 3, no. 2, doi:10.1038/NRI1000, ISSN 1474-1733, pages 123 - 132, XP009058496 [Y] 1-11,13 * page 124, column l, paragraph l *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents